| Issue Date |
Title |
Author(s) |
| 2014 |
The 104-Week Efficacy and Safety of Telbivudine-Based Optimization Strategy in Chronic Hepatitis B Patients: A Randomized, Controlled Study |
Sun, Jian;Xie, Qing;Tan, Deming;Ning, Qin;Niu, Junqi;Bai, Xuefan;Fan, Rong;Chen, Shijun;Cheng, Jun;Yu, Yanyan;Wang, Hao;Xu, Min;Shi, Guangfeng;Wan, Mobin;Chen, Xinyue;Tang, Hong;Sheng, Jifang;Dou, Xiaoguang;Shi, Junping;Ren, Hong;Wang, Maorong;Zhang, Hongfei;Gao, Zhiliang;Chen, Chengwei;Ma, Hong;Jia, Jidong;Hou, Jinlin |
| Mar-2020 |
Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy |
Fan, Rong;Zhou, Bin;Xu, Min;Tan, Deming;Niu, Junqi;Wang, Hao;Ren, Hong;Chen, Xinyue;Wang, Maorong;Ning, Qin;Shi, Guangfeng;Sheng, Jifang;Tang, Hong;Bai, Xuefan;Liu, Shi;Lu, Fengmin;Peng, Jie;Sun, Jian;Xie, Qing;Hou, Jinlin;Wan, Mobin;Chen, Shijun;Yu, Yanyan;Ma, Hong;Cheng, Jun;Zhang, Hongfei;Liu, Huimin;Gao, Zhiliang;Sun Yat-Sen;Dou, Xiaoguang |
| 2018 |
Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B |
Yu, Rui;Tan, Deming;Ning, Qin;Niu, Junqi;Bai, Xuefan;Chen, Shijun;Cheng, Jun;Yu, Yanyan;Wang, Hao;Xu, Min;Shi, Guangfeng;Wan, Mobin;Chen, Xinyue;Tang, Hong;Sheng, Jifang;Dou, Xiaoguang;Shi, Junping;Ren, Hong;Wang, Maorong;Zhang, Hongfei;Gao, Zhiliang;Chen, Chengwei;Ma, Hong;Jia, Jidong;Hou, Jinlin;Xie, Qing;Sun, Jian |
| 2013 |
Baseline Quantitative Hepatitis B Core antibody is the Strongest Predictor for 2-year HBeAg seroconversion in HBeAg Positive CHB Patients Treated with Telbivudine Alone or Combined with Adefovir |
Sun, Jian;Yuan, Quan;Xie, Qing;Fan, Rong;Tan, Deming;Ning, Qin;Niu, Junqi;Bai, Xuefan;Song, Liuwei;Chen, Shijun;Cheng, Jun;Yu, Yanyan;Wang, Hao;Xu, Min;Shi, Guangfeng;Wan, Mobin;Chen, Xin-Yue;Tang, Hong;Sheng, Jifang;Dou, Xiaoguang;Shi, Junping;Ren, Hong;Wang Maorong;Zhang, Hongfei;Gao, Zhiliang;Chen, Chengwei;Ma, Hong;Jia, Jidong;Xia, Ningshao;Hou, Jinlin |
| 2019 |
DOUBLE NEGATIVE HBV NUCLEIC ACID (DNA-/RNA-) PREDICTS OFF-TREATMENT DURABILITY OF NUCLES(T)IDE ANALOGUE IN A PROSPECTIVE COHORT |
Fan, Rong;Zhou, Bin;Xu, Min;Tan, Deming;Niu, Junqi;Wang, Hao;Ren, Hong;Chen, Xinyue;Wang, Maorong;Ning, Qin;Shi, Guangfeng;Sheng, Jifang;Tang, Hong;Bai, Xuefan;Liu, Shi;Lu, Fengmin;Peng, Jie;Sun, Jian;Xie, Qing;Hou, Jinlin |
| 2019 |
Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir |
Kong, Yuanyuan;Sun, Yameng;Zhou, Dialing;Wu, Xiaoning;Chen, Yongpeng;Piao, Hongxin;Lu, Lungen;Ding, Huiguo;Nan, Yuemin;Jiang, Wei;Xu, Youqing;Xie, Wen;Li, Hanwei;Feng, Bo;Shi, Guangfeng;Chen, Guofeng;Li, Hai;Zheng, Huanwei;Cheng, Jilin;Wang, Tailing;Liu, Hui;Lv, Fudong;Shao, Chen;Mao, Yimin;Sun, Jihong;Chen, Tao;Han, Tao;Han, Ying;Wan, Lin;Ou, Xiaojuan;Zhang, Hui;Jia, Jidong;You, Hong |
| 2015 |
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B |
Hou, Jin-Lin;Xu, Daozheng;Shi, Guangfeng;Wan, Mobin;Goodman, Zachary;Tan, Deming;Xie, Qing;Chen, Chengwei;Wei, Lai;Niu, Junqi;Wang, Qinhuan;Ren, Hong;Wang, Yuming;Jia, Jidong;Bao, Weibin;Dong, Yuhong;Trylesinski, Aldo;Naoumov, Nikolai V. |
| 2016 |
A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis |
Ma, Hong;Zeng, Minde;Han, Ying;Yan, Huiping;Tang, Hong;Sheng, Jifang;Hu, Heping;Cheng, Liufang;Xie, Qing;Zhu, Youfu;Chen, Guofeng;Gao, Zhiliang;Xie, Wen;Wang, Jiyao;Wu, Shanming;Wang, Guiqiang;Miao, Xiaohui;Fu, Xiaoqing;Duan, Liping;Xu, Jie;Wei, Lai;Shi, Guangfeng;Chen, Chengwei;Chen, Minhu;Ning, Qin;Yao, Chen;Jia, Jidong |
| 2016 |
A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144 |
Xu, Jinghang;Yu, Yanyan;Si, Chongwen;Zeng, Zheng;Li, Jun;Mao, Qing;Zhang, Dazhi;Tang, Hong;Sheng, Ji-Fang;Chen, Xinyue;Ning, Qin;Shi, Guangfeng;Xie, Qing;Zhang, Xiquan;Dai, Jun;Xu, Zhongnan |
| 2016 |
A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144 |
Xu, Jinghang;Yu, Yanyan;Si, Chongwen;Zeng, Zheng;Li, Jun;Mao, Qing;Zhang, Dazhi;Tang, Hong;Sheng, Ji-Fang;Chen, Xinyue;Ning, Qin;Shi, Guangfeng;Xie, Qing;Zhang, Xiquan;Dai, Jun;Xu, Zhongnan |
| 2015 |
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients |
Liang, Xieer;Cheng, Jun;Sun, Yongtao;Chen, Xinyue;Li, Tong;Wang, Hao;Jiang, Jianning;Chen, Xiaoping;Long, Hui;Tang, Hong;Yu, Yanyan;Sheng, Jifang;Chen, Shijun;Niu, Junqi;Ren, Hong;Shi, Junping;Dou, Xiaoguang;Wan, Mobin;Jiang, Jiaji;Xie, Qing;Shi, Guangfeng;Ning, Qin;Chen, Chengwei;Tan, Deming;Ma, Hong;Sun, Jian;Jia, Jidong;Zhuang, Hui;Hou, Jinlin |
| 2016 |
Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study |
Sun, Jian;Ma, Hong;Xie, Qing;Xie, Yao;Sun, Yongtao;Wang, Hao;Shi, Guangfeng;Wan, Mobin;Niu, Junqi;Ning, Qin;Yu, Yanyan;Zhou, Huijuan;Cheng, Jun;Kang, Wenzhen;Xie, Yi;Fan, Rong;Wei, Lai;Zhuang, Hui;Jia, Jidong;Hou, Jinlin |
